title: Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation.
authors: Miquel Blasco
authors: MB
authors: Pelicano
authors: Santiago Rodríguez
authors: SR
authors: de Córdoba
authors: Fritz
authors: F
authors: Diekmann
authors: Mercedes
authors: M
authors: Saiz
authors: Sara
authors: S
authors: Herrero
authors: Federic
authors: F
authors: Oppenheimer
authors: Josep M
authors: JM
authors: Campistol
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome; D003182:Complement C5 / Q000037:antagonists & inhibitors*; D017242:Complement Factor H / Q000235:genetics; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology; D019520:Living Donors; D020125:Mutation, Missense; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C493495:CFH protein, human; D003182:Complement C5; D051056:Complement Inactivating Agents; D017242:Complement Factor H; C481642:eculizumab